Compare Natera Inc. Common Stock (NTRA) vs Rubrik Inc. Class A Common Stock (RBRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Rubrik Inc. Class A Common Stock — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while Rubrik Inc. Class A Common Stock trades at $109.8 (market cap $23.61B). The key difference: Natera Inc. Common Stock is far larger — about 2.4× Rubrik Inc. Class A Common Stock's market cap, and Rubrik Inc. Class A Common Stock is more actively traded (2,764,516 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Rubrik Inc. Class A Common Stock for 4 Days on average.
| NTRA | RBRK | |
|---|---|---|
Market Cap | $57.03B | $23.61B |
Volume | 1,131,157 | 2,764,516 |
Sector | Health | Technology |
52-Week High | $425.64 | $125.80 |
52-Week Low | $179.42 | $43.81 |
Typical Hold Time | 0 Days | 4 Days |
Enterprise Value | $56.18B | $23.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Rubrik (RBRK) trades at $118.47, down 1.28% on the day, with strong technical momentum showing bullish moving averages and support at $118. The company demonstrates impressive revenue growth, with 2026 revenue reaching $1.5B and recent earnings beats, though profitability remains negative with a -16.5% net margin. Recent news highlights expansion of AI security offerings including Rubrik Code Guardian and strong institutional buying interest.
Rubrik presents a compelling growth story in cybersecurity with 100% analyst buy ratings and $105.08 consensus target, though current price exceeds this. Key risks include persistent losses despite revenue growth and competitive AI security landscape. The stock's technical strength and AI-driven demand create upside potential, but profitability concerns warrant careful monitoring of margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Rubrik Inc. Class A Common Stock
Rubrik provides data security and cyber recovery software for enterprises. Its platform protects data across on-premises, cloud, SaaS, and unstructured-data environments.
Read more on RBRK →
